Abbrea Capital’s Novartis NVS Stock Holding History

Abbrea Capital’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$1.24M	Sell	11,616 -140	-1%	-$14.1K	0.16%	104
2024 Q1	$1.18M	Hold	11,756	–	–	0.16%	114
2023 Q4	$1.19M	Hold	11,756	–	–	0.17%	106
2023 Q3	$1.2M	Hold	11,756	–	–	0.19%	100
2023 Q2	$1.19M	Hold	11,756	–	–	0.18%	101
2023 Q1	$1.08M	Hold	11,756	–	–	0.18%	107
2022 Q4	$1.07M	Hold	11,756	–	–	0.19%	107
2022 Q3	$894K	Sell	11,756 -75	-0.6%	-$6.22K	0.17%	111
2022 Q2	$1M	Hold	11,831	–	–	0.17%	108
2022 Q1	$1.04M	Hold	11,831	–	–	0.15%	115
2021 Q4	$1.03M	Hold	11,831	–	–	0.14%	122
2021 Q3	$968K	Hold	11,831	–	–	0.14%	113
2021 Q2	$1.08M	Hold	11,831	–	–	0.16%	105
2021 Q1	$1.01M	Hold	11,831	–	–	0.17%	100
2020 Q4	$1.12M	Buy	11,831 +331	+3%	+$28.9K	0.2%	91
2020 Q3	$1M	Sell	11,500 -215	-2%	-$18.6K	0.21%	90
2020 Q2	$1.02M	Hold	11,715	–	–	0.23%	87
2020 Q1	$966K	Hold	11,715	–	–	0.26%	87
2019 Q4	$1.11M	Hold	11,715	–	–	0.24%	91
2019 Q3	$1.02M	Hold	11,715	–	–	0.24%	91
2019 Q2	$1.07M	Buy	+11,715	New	+$992K	0.26%	88

Other funds holding NVS

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CCM

Cullen Capital Management New York $10.2B AUM 27.15% 1-Year Est. Return

Abbrea Capital's NVS Position: Q2 2024 in Review

Abbrea Capital reduced its Novartis (NVS) stake by 1.2% in Q2 2024, selling an estimated $14.1K and leaving 11,616 shares worth $1.24M. The position accounts for 0.16% of the portfolio, ranked #104.

Abbrea Capital first reported a position in NVS in Q2 2019 and has held it in 21 quarters since. 1,307 funds tracked by Wall St. Rank hold NVS as of Q2 2024.

Abbrea Capital held 11,616 shares of Novartis worth $1.24M as of Q2 2024.
Abbrea Capital sold 140 Novartis shares in Q2 2024, an estimated $14.1K.
Novartis made up 0.16% of Abbrea Capital's portfolio in Q2 2024, its #104 holding.
Abbrea Capital first reported a position in Novartis in Q2 2019 and has held it in 21 quarters since.
1,307 funds tracked by Wall St. Rank held Novartis as of Q2 2024.

Based on Abbrea Capital's 13F filing for Q2 2024, filed 8 Aug 2024.